Spindler KG, Appelt AL, Pallisgaard N, Andersen RF, Jakobsen A (2013) KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer. Br J Cancer 109: 3067–3072.

Spindler KL, Pallisgaard N, Vogelius I, Jakobsen A (2012) Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res 18: 1177–1185.

Taly V, Pekin D, Aled AE, Laurent-Puig P (2012) Detecting biomarkers with microdroplet technology. Trends Mol Med 18: 405–416.

*Correspondence: Dr D Tougeron; E-mail: davidtougeron@hotmail.fr
Published online 11 March 2014
© 2014 Cancer Research UK. All rights reserved 0007 – 0920/14

Spindler KL, Pallisgaard N, Pallisgaard N, Andersen RF, Jakobsen A (2013) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486: 537–540.

Hansen TF, Andersen RF, Pallisgaard N, Spindler K-LG, Pleon J, Keldsen N, Lindbjerg J, Sorensen FB, Jakobsen A (2014) A three-weekly schedule of irinotecan and panitumumab as third-line treatment for patients with wild type KRAS metastatic colorectal cancer: Results from a phase II trial. Colorectal Cancer (in press).

Spindler KL, Pallisgaard N, Andersen R, Pleon J, Jakobsen A (2013c) Gemcitabine and Capecitabine for chemotherapy refractory colorectal cancer—results of a phase II and translational research study. J Cancer Ther 4(6): 44–50.

Spindler KG, Appelt A, Pallisgaard N, Andersen R, Jakobsen A (2013a) Quantitative Cell Free DNA, KRAS and BRAF mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan. Clin Cancer Res 18(4): 1177–1185.

Spindler KL, Pallisgaard N, Andersen RF, Pleon J, Jakobsen A (2013b) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486: 532–536.

Spindler KL, Pallisgaard N, Andersen R, Pleon J, Jakobsen A (2013c) Pemetrexed and gemcitabine for chemotherapy refractory colorectal cancer—results of a phase II and translational research study. J Cancer Ther 4(6): 44–50.

Spindler KL, Pallisgaard N, Vogelius I, Jakobsen A (2012) Quantitative Cell Free DNA, KRAS and BRAF mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan. Clin Cancer Res 18(4): 1177–1185.

Spindler KL, Sorensen M, Pallisgaard N, Andersen R, Havelund BM, Pleon J, Lassen U, Jakobsen A (2013d) Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma. Acta Oncol 52(5): 963–970.

Spindler KL, Pallisgaard N, Andersen RF, Jakobsen A (2012) Changes of mutational status during third line treatment for metastatic colorectal cancer. EMCC The 6th European Multidisciplinary Conference on Colorectal cancer. Prag April 15–17 2012. Oral presentation.

Tougeron D, Lecomte T, Pages JC, Villalva C, Collin C, Ferru A, Tourani JM, Silvain C, Levillain P, Karayan-Tapon L (2013) Effect of low-frequency KRAS mutations on response to anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol 24: 1267–1273.

Tougeron D, Laurent-Puig P, Zaanan A (2014) Comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer’. Br J Cancer 111(12): 2379–2380.

*Correspondence: K-LG Spindler; E-mail: kg.spindler@rm.dk
Current address: Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
Published online 11 March 2014
© 2014 Cancer Research UK. All rights reserved 0007 – 0920/14

http://creativecommons.org/licenses/by-nc-sa/3.0/